Abstract: Traditional medicine and medicinal plants, in general, continue to be a powerful source of new drugs, now contributing about 90% of the newly discovered pharmaceuticals. Traditional medicine continues to provide health coverage for over 80% of the world population, especially in the developing world. The past and the present are all full of living examples of discoveries of drugs, ranging from anticancer, antiasthma, antidiabetic, antihypertensives and many others which owe their origin to traditional medicine. The current era of HIV/AIDS is not short of contributions from traditional medicine. The recent discovery of the non-nucleoside reverse transcriptase inhibitor (NNRTI), calanolide A, is a new addition from traditional medicine. Many more such discoveries are yet to come. While this potential is much acknowledged, little has been done in African countries, to utilize the plants that are already known and proven to be safe for use by patients. A number of plants could be widely cultivated for local industrial production of medicines and herbal nutritional supplements. There is need to ensure that what is known is made use of, for financial gain, and for improvement of the health of our people. We need to establish the necessary expertise for development of traditional medicines and deliberate efforts should be made to encourage local industrial production of traditional/herbal medicines so that cultivation may become possible and hence contribute to poverty reduction.
Introduction
The world is currently facing a number of health challenges, partly due to expanded boundaries of diseases as a result of global warming, improved means of transportation and increased migration of people. It is also acknowledged that the change of lifestyle in the developing world, where people are now leading sedentary lives, and have greatly changed types of food essentially consuming more refined foods has now led to increase in the prevalence of glucose intolerance (King & Rewers, 1993) . Likewise there have emerged new diseases such as HIV/AIDS, Ebola, and human spongiform encephalopathy (Budka et al., 1995; Van Everbroeck et al., 2000; Brown et al., 2004 ) that do not yet have a cure. Re-emergence of diseases like tuberculosis and the emergence of pathogens that are resistant to the currently available chemotherapeutic agents, is yet another challenge of our times. The living example is the emergence of multi-drug resistant (MDR) Mycobacterium tuberculosis. Malignant tumors and some important parasites, like Plasmodium falciparum and Candida albicans are also developing resistance, thus making management of diseases more and more difficult.
Amidst this crisis, the synthetic chemist is long recognized to have failed to address these health challenges. The only rational alternative is therefore, traditional medicine, which according to WHO supports more than 80% of the population in developing countries, and it is now widely accepted that traditional medicines are more affordable, less toxic, and have a wide acceptance around the world (Cowan, 1999; WHO, 2002) .
Nature has been a source of medicinal treatments for thousands of years, and plant-based systems continue to play an essential role in the primary health care. It is estimated that 25 to 50% of all current pharmaceuticals are derived from plants (Cowan, 1999) . In fact, it is now believed that plant based systems contribute 90% of the newly discovered pharmaceuticals. Nature has provided many of the effective anticancer agents in current use, such as the microbially derived drugs, dactinomycin, bleomycin, and doxorubicin, and the plant-derived drugs vinblastine, irinotecan, topotecan, etoposide, and paclitaxel (Cragg et al., 1997) . Traditional medicine, has particularly, been a good source of these plant derived drugs. This paper examines some evidences and indicators of prospects for the use of traditional medicines in the management of different diseases, and some efforts in the discovery of drugs for the management of HIV/AIDS and associated opportunistic conditions. Literature reports and some results generated from our own research have been used to build up a case for the possibility that traditional medicine could be a source of drugs for the management of patients in Tanzania.
Traditional medicine in the discovery of anticancer drugs
One good example is the plant Catharanthus rosea which was used in Madagascar for treatment of diabetes. Through use, it was later observed that extracts of the plant suppress the bone marrow. Follow up of this observation led to the discovery and the isolation of the anticancer compounds vincristine, vinblastine, and vinorelbine. The compound taxol which was first isolated from the Pacific yew, Taxus brevifolia, was found to have anticancer activity. This has now resulted in the synthesis of the analogues paclitaxcel and docetaxel, which now constitute a new class of broad spectrum anticancer compounds.
Plants of the family Combretaceae are widely used in traditional medicine in South Africa (Eloff, 1999) and Tanzania (Fyhrquist et al., 2004; Moshi & Mbwambo, 2005) . The plants of this family are now a source of combretastatins, a new class of antimitotic drugs that also inhibit angiogenesis and are currently being developed for the treatment of cancer. Work done in our laboratory has shown that Terminalia sericea (Moshi & Mbwambo, 2005) and Terminalia mollis (M. Moshi & Z. Mbwambo, unpublished) , which are used in traditional medicine in Tanzania have potential to yield anticancer compounds. Work done using brine shrimps as a screening tool shows that extracts of the two plants have activity which compares very favorably with the standard drug cyclophosphamide (Table 1) . Ongoing studies on the combretastatins, and other compounds, from this family hold a promise for new anticancer drugs.
Traditional medicine in the discovery of antimalarial drugs
Cinchona bark was used for the treatment of malaria by South American Indians. This led to the isolation of quinine in the seventeenth century. Based on the structure of quinine other analogues have been synthesized. Mefloquine is a quinoline methanol with a structure similar to that of quinine. Other antimalarials which were synthesized based on the structure of quinine include the 4-aminoquinolines (chloroquine and amodiaquine), 8-aminoquinolines (primaquine and tefenaquine), and the aryl alcohols (halofantrine, lumefantrine, and pyronaridine). Recently, from the Chinese traditional medicine, quinghasou, the antimalarials artemisinin, dihydroartemisinin, artemether, and arteether have been discovered (Meshnick et al., 1996) . A number of other plants from traditional medicine have shown antimalarial activity and have potential for discovery of future antimalarials. 
Traditional medicine in the discovery of anti-asthma drugs
Khellin from Amni visnaga was used in the USA as a bronchodilator. It was then discovered that after prolonged use it produces nausea and vomiting. As an attempt to synthesize khellin analogues with fewer side effects the antiasthma drug chromolyn (Sodium chrogycate was discovered (Sneader, 1985) . Sodium chromogylycate is now used to stabilize the membranes of macrophages and prevent degranulation, and hence release of mediators of broncho-constriction in asthmatic patients.
Traditional medicine in the discovery of antidiabetic drugs
Galega officinalis (L.) was used ethnomedically for the treatment of diabetes. Phytochemical work led to the isolation of the antihyperglycaemic compound galegine from the plant. Further structure activity studies and modification of galegine led to the synthesis of metformin and eventually the other biguanide oral hypoglycaemic agents (Sneader, 1985) . Harunganin was recently isolated from a Tanzanian plant, Harungana madagascariensis and is now patented in the USA for treatment of diabetes (Inman & Luo, 1998) .
Other compounds recently isolated from traditionally used plants and patented for treatment of diabetes include cryptolepine (Bierer et al., 1998a,b; Luo et al., 1998 ), maprouneacin (Carney et al., 1999 , 3ß,30-dihydroxylupen-20(29)-en-2-one (Inman & Reed, 1997 , vismin (Inman & Luo, 1998) , and quinones SP18904 and SP18905 (Luo et al., 1999) . The most interesting discovery was nordihydroguaiaretic acid (ndga) which, besides being active orally in diabetic mice, also lowered cholesterol levels.
Traditional medicine in the discovery of anti-HIV drugs
The use of traditional medicines for the management of HIV/AIDS patients is directed to three main areas; direct effect on the virus, immunostimulant activity, and treatment of opportunistic infections. A number of plants have now been identified from random screening or from traditional systems of treatment that interfere with nearly all stages of the viral life cycle. Compounds have been reported that inhibit virus-cell fusion, reverse transcription, virus adsorption, and proteolytic cleavage (Vlietinck et al., 1998; Wang et al., 1998; Uchiumi et al., 2003) . A good number of plants containing these compounds, such as Phyllanthus amarus (Notka et al., 2004) , Phyllanthus niruri (Naik & Juvekar, 2003) , Salvia miltiorrhiza (Abd-Elazem et al., 2002) , Shepherdia argentea (Yoshida et al., 1996) , Viola yedoensis, Arctium lappa, Epimedium grandiflorum, Glycyrrhiza uralensis and Castanospermum australe (WHO, 1989) , and Croton tiglium (Nakamura, 2004) originate from traditional medicine. Other traditionally used medicines that have shown anti-HIV activity are Aspilia pluriseta and Rumex bequaertii (Cos et al., 2002) . In a recent study done on 21 plant species belonging to 14 families of plants, that are used in Ethiopian traditional medicine, extracts of four plants, Bersama abyssinica Fresen, Combretum paniculatum Vent., Dodonaea angustifolia L.f., and Ximenia americana L. displayed anti-HIV activity against both HIV-1 and HIV-2 strains (Asres et al., 2001) . Similarly screening of plants used in traditional medicines of other countries has led to identification of interesting anti-HIV activity (Abdel-Malek et al., 1996; Piras et al., 1997; Li et al., 1993) .
The most recent success story is the discovery of (+)-Calanolide A, a novel non-nucleoside HIV-1-reverse transcriptase inhibitor (NNRTI), which was first isolated from a Malaysian plant, Calophyllum lanigerum (Currens et al., 1996; Buckheit et al., 1999; Creagh et al., 2001 (Harnett et al., 2005) . Clinicians treating HIV+ patients with Sutherlandia tablets produced by the South African company Phyto Nova have reported increase in CD4 and reduction of viral load. Sutherlandia is also reported to have apoptotic activity against human cancer cell lines (Chinkwo, 2005) , thus suggesting an additional potential for dealing with opportunistic malignancies in HIV patients.
Aloe vera has also being very popular in South Africa. The plant contains a large variety of amino acids, enzymes, vitamins and minerals and it comes closer than any other known plant to the duplication of life's essential substances in the biochemistry of the human body. It has natural healing and detoxifying powers and works gently within the intestinal tract to help break down impacted food residues and thoroughly cleanse the bowel. It can help ease constipation and prevent continuing diarrhoea, setting a regularity to the bowel. All this helps to reduce discomfort and bloating. Naturally, as these symptoms are eased, so the stress associated with the discomfort is also reduced. Aloe vera is a stimulant to the immune system, a powerful antiinflammatory, and analgesic and is able to speed up cell growth. Aloe vera contains a large number of mucopolysaccharides (basic sugars) which are found in every cell in the body and contains large numbers of nutrients including vitamins E, C, B1, 2, 3, and 6 as well as iron, manganese, calcium and zinc. Seven essential amino acids and fatty acids are also found in Aloe vera (Davis & Leitner, 1989; Davis & Rosenthal, 1989; Pulse & Uhlig, 1990; Sato, 1990; McCluggage & Higdon, 1999) . This plant should be promoted as a nutritional supplement to HIV/AIDS patients, who are likely to realize a lot of benefit from its use. The big question is whether such use may not have interactions, particularly with concurrent use with anti-retroviral drugs. However, this should be one of the areas that need intensive scientific studies.
Traditional medicines in the treatment of bacterial infections
The other area where traditional medicines can offer hope is in the treatment of opportunistic infections. Our experience shows that there are a number of plants with a good potential for offering solutions to resolution of bacterial, fungal, viral, protozoa, and other opportunistic infections. There are now abundant reports of useful activities of plants of the genera Combretum and Terminalia. A number of species of Combretum and Terminalia from South Africa have antibacterial activity (Eloff, 1999) . The plants in the two genera are heavily used in traditional medicine in South Africa with an annual consumption of 20.2 tons per year in Kwazulu Natal (Eloff, 1998) . In Tanzania the plants in the two genera are also popularly used in traditional medicine for the treatment of bacterial infections (Fyhquist et al., 2004 (Fyhquist et al., , 2005 Moshi & Mbwambo, 2005) . Combretum micranthum which is used traditionally in West Africa for treatment of biliary fever, colic and vomiting, showed good antibacterial activity against both gram positive and gram negative bacteria.
In a recent study we looked at the antibacterial properties of Terminalia sericea (Moshi & Mbwambo, 2005) and Terminalia mollis (unpublished results), in which we showed that these two plants growing in Tanzania have antimicrobial activity, thus confirming reports from traditional healers in Iringa, Tabora and Bukoba where they were collected. The two plants are used for treatment of bacterial infections such as gonorrhoea and tuberculosis, and also dysentery, diarrhoea and malaria.
Traditional medicines for treatment of fungal infections
A number of plants used in traditional medicines are currently being identified for the treatment of opportunistic fungal infections in HIV patients (Fyhrquist et al., 2004; Motsei et al., 2003) . Some of the already identified plants could be used as oral mouth preparations (Motsei et al., 2003) , and others could be made in the form of ointments or creams for use on the skin. Studies done on some Tanzania have also indicated possibility that they may be good for treatment of fungal infections. These plants and others are currently being screened for toxicity using the brine shrimps test in our laboratory. The preliminary results show that a good number of the plants for treatment of fungal infections have a good safety margin ( Table 2) . Some of these plants are being tested for the treatment of topical fungal infections, and already there are good responses among patients using them.
Efforts to use already established plants
Prospects for incorporating traditional medicines into the health care system are quite high, if appropriate measures are taken to ascertain the claimed activities, and obvious toxicities that may prevent immediate use. In many instances traditional healers use these plants in a manner that avoids the toxic manifestations. Biological testing coupled with a quick evaluation for toxicity should allow an accelerated use of traditional medicines without a lot of fear about toxicity, especially where such medicines are going to be used for a short period, such as in the treatment of bacterial, fungal and protozoan infections. For example, Terminalia sericea gave positive antibacterial activity against gram positive and gram negative bacteria and antifungal activity against C. albicans, but it also showed toxicity on brine shrimps, suggesting either outright toxicity or presence of anticancer activity, since the results compared very well with the values obtained with the standard anticancer drug cyclophosphamide (Moshi & Mbwambo, 2005) . It is known that Combretaceae plants contain combretastatins, which have anticancer activity.
Our Institute is now piloting the production of herbal formulations of already proven plants. Currently herbal preparations for benign prostatic hypertrophy, peptic ulcers, coughing, livers cirrhosis and asthma are being produced at the Institute. Efforts are underway to standardize these formulations and make them available to many more people in Tanzania. The production is going hand in hand with promotion of cultivation of some of the medicinal plants such as Adansonia digitata, Moringa oleifera, Hibiscus subdariffa variety Rosera, and Aloe vera. It is expected to involve the community in the cultivation of these medicinal plants.
Conclusion
Traditional medicines are now the mainstay of drug discovery, for treatment of old and emerging diseases. The options of using them as herbal medicines or for isolation of patentable compounds remain attractive to researchers in Tanzania and elsewhere. However, there is need to ensure that what is known is made use of, for financial gain, and for improvement of the health of our people. We need to establish the necessary expertise for development of traditional medicines and deliberate efforts should be made to encourage local industrial production of traditional/herbal medicines so that cultivation may become possible and hence contribute to poverty reduction. 
